14th February 2013

Aurobindo Pharma receives USFDA Finals Approvals for Pioglitazone Tablets and Pioglitazone Hydrochloride + Metformin Hydrochloride Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Pioglitazone Tablets USP 15mg, 30mg & 45mg (ANDA 200268) and its earlier tentatively approved Pioglitazone Hydrochloride + Metformin Hydrochloride Tablets, 15mg(base)/500mg & 15mg(base)/850mg (ANDA 200823). The products are ready for launch.

Pioglitazone Tablets USP 15mg, 30mg, 45mg and Pioglitazone Hydrochloride + Metformin Hydrochloride Tablets, 15mg(base)/500mg, 15mg(base)/850mg are the generic equivalents of Takeda Global Research Development Center Inc's Actos® Tablets 15mg, 30mg, 45mg and Actoplus Met® Tablets, 15mg (base)/500mg, 15mg (base)/850mg respectively. The products are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. The combined market size of the products is approximately US$ 2.8 Billion for the twelve months ending September 2012 according to IMS.

Aurobindo now has a total of 177 ANDA approvals (152 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com